Skip to main content

Pipeline

A pipeline of innovative products

*  PSB205 (QL1706) Status: Approved and marketed in China to treat patients with recurrent or metastatic cervical cancer.

More About PSB205

+ PSB114 (QLP2117) Status: IND cleared by NMPA in China; Phase 1b/II clinical trials are ongoing.

More About PSB114

^ PSB219 (QLP3119) Status: IND cleared for clinical studies by FDA in US and NMPA in China.

More About PSB219